QuickView for AHSA1;jsessionid=BB00502B7E785F08F8DBB588B0A0C812;jsessionid=8CAE4D2F6D2ADAA7000690C3A4BABDF2;jsessionid=59527D2BB9ADB40D0FF86D690D2CAA77;jsessionid=4611458D3173AC9A7FB1296B151D0C12;jsessionid=636E97E918E33141C83BCCD0DC6CB41A;jsessionid=C6B448336D132A38353F6D230A5116BD;jsessionid=CE7115741B98B088E4048D7E2ED4E3FC;jsessionid=FF378B1257382F5801E5602FB50EF87A;jsessionid=4A797AE0AA18A440615501F3FE90AE50;jsessionid=CE3530EC9F383D23C39ABD8BFDDF0A80;jsessionid=6200630C585178810FAB031792A7817A;jsessionid=800F1050EC2AFDBF8EB01A95EE80AAD1 (gene)

1. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistan…
2. Hsp90 co-chaperones, FKBP52 and Aha1, promote tau pathogenesis in aged wild-type mice.
3. Co-chaperones TIMP2 and AHA1 Competitively Regulate Extracellular HSP90:Client MMP2 Activity and Mat…
4. A chemical compound inhibiting the Aha1-Hsp90 chaperone complex.
5. Cooperative Nucleotide Binding in Hsp90 and Its Regulation by Aha1.

There were no clinical trials for AHSA1;jsessionid=BB00502B7E785F08F8DBB588B0A0C812;jsessionid=8CAE4D2F6D2ADAA7000690C3A4BABDF2;jsessionid=59527D2BB9ADB40D0FF86D690D2CAA77;jsessionid=4611458D3173AC9A7FB1296B151D0C12;jsessionid=636E97E918E33141C83BCCD0DC6CB41A;jsessionid=C6B448336D132A38353F6D230A5116BD;jsessionid=CE7115741B98B088E4048D7E2ED4E3FC;jsessionid=FF378B1257382F5801E5602FB50EF87A;jsessionid=4A797AE0AA18A440615501F3FE90AE50;jsessionid=CE3530EC9F383D23C39ABD8BFDDF0A80;jsessionid=6200630C585178810FAB031792A7817A;jsessionid=800F1050EC2AFDBF8EB01A95EE80AAD1